Marqibo
Used for Leukemia
Used for Leukemia
Marqibo (liposomal vincristine) is a medication used to treat adults with a blood and bone marrow cancer called Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL). It's typically given if the cancer comes back or has gotten worse even after trying other anticancer medications. Marqibo (liposomal vincristine) has been discontinued and is no longer available in the United States.
What is Marqibo (liposomal vincristine)?
What is Marqibo (liposomal vincristine) used for?
- Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) in people whose cancer has returned or worsened after previous therapies
How Marqibo (liposomal vincristine) works
Marqibo (liposomal vincristine) is a vinca alkaloid. It works by binding to a protein called tubulin, which then slows or stops cancer cells from growing and spreading.
Drug facts
| Common Brands | Marqibo |
|---|---|
| Drug Class | Vinca alkaloid |
| Controlled Substance Classification | Not a controlled medication |
| Generic Status | No lower-cost generic available |
| Availability | Discontinued |
